SCHEMBL3399447

SCHEMBL3399447

O=c1cc(CCl)oc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.63
CYP11B1 P15538 2/20 0.58
CYP11B2 P19099 2/20 0.58
SIGMAR1 Q99720 2/20 0.57
TNKS O95271 6/20 0.51
NPC1 O15118 5/20 0.51
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
GABRP O00591 3/20 0.51
GABRD O14764 3/20 0.51
GABRA1 P14867 3/20 0.51
GABRB1 P18505 3/20 0.51
GABRG2 P18507 3/20 0.51
GABRB3 P28472 3/20 0.51
GABRA5 P31644 3/20 0.51
GABRA3 P34903 3/20 0.51
GABRA2 P47869 3/20 0.51
GABRB2 P47870 3/20 0.51
GABRA4 P48169 3/20 0.51
GABRE P78334 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803387 1.00 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL12324682 0.85 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL3715533 0.82 PPARG (0.69) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL30694898 0.82 PPARG (0.69) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL30876965 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL3814678 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL3395103 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL5695477 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL9972758 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS
SCHEMBL9471231 0.81 PPARG (0.63) PPARGCYP11B1CYP11B2SIGMAR1TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4090654-B1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LTD (IN) 2025-07-09 EP claimed
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds LUPIN LIMITED (IN) 2025-07-01 US claimed
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 CN claimed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US claimed
EP-4090654-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS Lupin Limited (IN) 2022-11-23 EP claimed
CN-114981253-A Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2022-08-30 CN claimed
WO-2021144814-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2021-07-22 WO claimed
EP-3253750-B1 NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2019-04-10 EP claimed
EP-4090654-B1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LTD (IN) 2025-07-09 EP disclosed
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds LUPIN LIMITED (IN) 2025-07-01 US disclosed
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 CN disclosed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US disclosed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US disclosed
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS LUPIN LIMITED (IN) 2023-05-04 US disclosed
EP-0632035-A1 Aminoalkylchomones, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1995-01-04 EP disclosed
EP-0580503-A1 Aminoalkylchromones, process for their preparation and compositions containing them ADIR ET COMPAGNIE (FR) 1994-01-26 EP disclosed
US-5082849-A Antiinflammatory agents or antiallergens AVENTIS PHARMACEUTICALS INC. 1992-01-21 US disclosed
EP-0434827-A1 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-07-03 EP disclosed
WO-1991001123-A2 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? RORER INTERNATIONAL (OVERSEAS) INC. (US) 1991-02-07 WO disclosed
US-4977162-A Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments RORER PHARMACEUTICAL CORPORATION (US) 1990-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140054-A1 METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS CASR, CALCR, RYR1 PPARG 824/4885CYP11B1 571/4885CYP11B2 686/4885
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds CASR, CALCR, RYR1 PPARG 824/4885CYP11B1 571/4885CYP11B2 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.